FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer-Reference-Cited by-同舟云学术

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Published:2018-12-20 Issue:25 Volume:379 Page:2395-2406
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Conroy Thierry¹,Hammel Pascal¹,Hebbar Mohamed¹,Ben Abdelghani Meher¹,Wei Alice C.¹,Raoul Jean-Luc¹,Choné Laurence¹,Francois Eric¹,Artru Pascal¹,Biagi James J.¹,Lecomte Thierry¹,Assenat Eric¹,Faroux Roger¹,Ychou Marc¹,Volet Julien¹,Sauvanet Alain¹,Breysacher Gilles¹,Di Fiore Frédéric¹,Cripps Christine¹,Kavan Petr¹,Texereau Patrick¹,Bouhier-Leporrier Karine¹,Khemissa-Akouz Faiza¹,Legoux Jean-Louis¹,Juzyna Béata¹,Gourgou Sophie¹,O’Callaghan Christopher J.¹,Jouffroy-Zeller Claire¹,Rat Patrick¹,Malka David¹,Castan Florence¹,Bachet Jean-Baptiste¹

Affiliation:

1. From the Institut de Cancérologie de Lorraine and Université de Lorraine (T.C.) and Centre Hospitalier Universitaire (L.C.), Nancy, Hôpital Beaujon and University Paris VII, Clichy (P.H., A.S.), Hôpital Huriez, Lille (M.H.), Centre Paul Strauss, Strasbourg (M.B.A.), Institut Paoli-Calmettes, Marseille (J.-L.R.), Centre Antoine-Lacassagne, Nice (E.F.), Hôpital Jean-Mermoz, Lyon (P.A.), Hôpital Trousseau, Tours (T.L.), Centre Hospitalier Universitaire de Saint-Eloi (E.A.) and Institut du Cancer de...

Funder

Canadian Cancer Society

Institut National du Cancer

7 Days in May

French National League against Cancer

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1809775

Cited by 1881 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cross-sectional imaging after pancreatic surgery: The dialogue between the radiologist and the surgeon;European Journal of Radiology Open;2024-06

2. Multi-institutional review of adverse events associated with irreversible electroporation in the treatment of locally advanced pancreatic cancer;Surgery;2024-03

3. CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy;Cancer Letters;2024-03

4. Molecular pathology and protein markers for pancreatic cancer: relevance in staging, in adjuvant therapy, in determination of minimal residual disease, and follow-up;Hepatobiliary Surgery and Nutrition;2024-02

5. The prognosis-based classification model in resectable pancreatic cancer;Surgical Oncology;2024-02